J Liq Biopsy. 2026 Sep 18;14:100501. doi: 10.1016/j.jlb.2026.100501. eCollection 2026 Dec.

ABSTRACT

INTRODUCTION: Circulating tumor DNA (ctDNA) is a valuable tool for assessing minimal residual disease (MRD) and predicting recurrence in resected non-small cell lung cancer (NSCLC) patients. Combining ctDNA-detection with radiological tumor volume may improve risk stratification.

METHODS: Patients with stage I-III resectable NSCLC were prospectively enrolled in the RESIDUAL study. Plasma samples were collected before surgery (T0), at landmark (10 days after surgery), during surveillance (T2, 20 days, T3, 1 months after surgery and every 3 months for the first year and then at the end of the second year after surgery), and at relapse. Samples were analyzed using Guardant Reveal, a tissue-free methylation-based ctDNA assay. Receiver operating characteristic analysis associated T1 ctDNA status with tumor volume; volume thresholds were calculated via Youden's J, and Cox regression analysis was performed.

RESULTS: Forty-eight patients were enrolled (median age 72 years; 64.6% male). Most had stage I disease (54.2%) and adenocarcinoma histology (79.2%). Median follow-up was 41.8 months, and 19 patients (39.6%) relapsed. Overall ctDNA detection rate was 15.2% across all timepoints. Pre-surgical ctDNA detection was higher in squamous histology and stage II-III disease and was associated with worse disease-free survival (DFS; p = 0.022). Landmark MRD detection was also associated with worse DFS (p = 0.024). Serial surveillance sampling anticipated radiologic recurrence by a median of 2.6 months (range 2.0-7.5). Patients with tumor volume >26,378 mm³ had a significantly higher relapse risk (p < 0.001).

CONCLUSIONS: MRD detection in NSCLC resected patients predicts relapse and poor outcome; integrating ctDNA with tumor volume enhances identification of high-risk patients.

PMID:42828040 | PMC:PMC13631347 | DOI:10.1016/j.jlb.2026.100501